文献速递心外重症与机械循环支持

比伐芦定在儿童心室辅助装置中的成本效益

Cost-effectiveness of bivalirudin in pediatric ventricular assist devices.
PubMed 文献 · J Heart Lung Transplant · 2022-10-12

该研究基于儿科健康信息系统2009至2021年691例0至6岁心室辅助装置(VAD)患儿,比较比伐芦定与肝素的使用趋势、结局、资源利用和成本效益。比伐芦定使用率从2009年至2021年显著上升,2021年达90%;比伐芦定组院内死亡率26% vs 肝素组32%(校正SHR 0.57,95%CI 0.40-0.83),增量成本效益比(ICER)为每获得一个质量调整生命年61192美元(范围27673至131243美元)。

要点

  • 691例儿童VAD中304例(44%)使用比伐芦定,2021年使用比例达90%(趋势P<0.01)。
  • 比伐芦定组院内死亡率26% vs 肝素组32%(校正SHR 0.57,95%CI 0.40-0.83)。
  • 比伐芦定组VAD后住院中位天数91天 vs 肝素组64天(P<0.001),但每日成本更低(成本比0.87,95%CI 0.79-0.96)。

核心结论

  • 比伐芦定使用在过去十年显著增加,现用于90%的儿童VAD接受者。
  • 比伐芦定与显著降低的院内死亡率相关,且ICER低于65000美元,使其成为儿童VAD接受者的一种成本效益治疗。

研究设计与样本

  • 基于儿科健康信息系统的回顾性队列研究,纳入2009至2021年691例0至6岁接受VAD的儿童。
  • 使用趋势分析评估比伐芦定使用,采用Fine-Gray亚分布风险比(SHR)比较结局,因住院时长差异比较每日医院成本,并计算增量成本效益比(ICER)。

主要发现

  • 691例患儿中位年龄1岁(IQR 0-2),304例(44%)接受比伐芦定,2021年90%接受比伐芦定(趋势P<0.01)。
  • 比伐芦定组院内死亡率26% vs 肝素组32%(校正SHR 0.57,95%CI 0.40-0.83),VAD死亡率20% vs 27%(校正SHR 0.46,95%CI 0.32-0.77),校正年份、年龄、诊断和中心VAD量。
  • 比伐芦定组VAD后住院中位天数91天 vs 肝素组64天(P<0.001)。
  • 比伐芦定组每日成本中位数更低(成本比0.87,95%CI 0.79-0.96),药房成本较高被影像、实验室、供应和食宿成本较低所抵消。
  • 比伐芦定 vs 肝素的ICER为每获得一个质量调整生命年61192美元(范围27673至131243美元)。

临床怎么用

  • 作者认为比伐芦定与显著降低的院内死亡率相关且ICER低于65000美元,使其成为儿童VAD接受者的一种成本效益治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite recent data suggesting improved outcomes with bivalirudin vs heparin in pediatric Ventricular assist devices (VAD), higher costs remain a barrier. This study quantified trends in bivalirudin use and compared outcomes, resource utilization, and cost-effectiveness associated with bivalirudin vs heparin. METHODS: Children age 0 to 6 year who received VAD from 2009 to 2021 were identified in Pediatric Health Information System. Bivalirudin use was evaluated using trend analysis and outcomes were compared using Fine-Gray subdistrubtion hazard ratios (SHR). Daily-level hospital costs were compared due to differences in length of stay. Cost-effectiveness was evaluated using incremental cost-effectiveness ratio (ICER). RESULTS: Of 691 pediatric VAD recipients (median age 1 year, IQR 0-2), 304 (44%) received bivalirudin with 90% receiving bivalirudin in 2021 (trend p-value <0.01). Bivalirudin had lower hospital mortality (26% vs 32%; adjusted SHR 0.57, 95% CI 0.40-0.83) driven by lower VAD mortality (20% vs 27%; adjusted SHR 0.46, 95% CI 0.32-0.77) after adjusting for year, age, diagnosis, and center VAD volume. Post-VAD length of stay was longer for bivalirudin than heparin (median 91 vs 64 days, respectively, p < 0.001). Median daily-level costs were lower among bivalirudin (cost ratio 0.87, 95% CI 0.79-0.96) with higher pharmacy costs offset by lower imaging, laboratory, supply, and room/board costs. Estimated ICER for bivalirudin vs heparin was $61,192 per quality-adjusted life year gained with a range of $27,673 to $131,243. CONCLUSIONS: Bivalirudin use significantly increased over the past decade and is now used in 90% young pediatric VAD recipients. Bivalirudin was associated with significantly lower hospital mortality and an ICER <$65,000, making it a cost-effective therapy for pediatric VAD recipients.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Burstein D, Kimmel S, Putt M, et al. Cost-effectiveness of bivalirudin in pediatric ventricular assist devices. J Heart Lung Transplant. 2022. PMID: 36333207. doi:10.1016/j.healun.2022.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。